Get the Stockscreener App
0.1957
3.26%
-0.0066
Pre-market:
.20
0.0043
+2.20%
Liminatus Pharma Inc stock is traded at $0.1957, with a volume of 609.99K.
It is down -3.26% in the last 24 hours and down -18.08% over the past month.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
See More
Previous Close:
$0.2023
Open:
$0.205
24h Volume:
609.99K
Relative Volume:
0.08
Market Cap:
$7.70M
Revenue:
-
Net Income/Loss:
$-2.58M
P/E Ratio:
-1.0561
EPS:
-0.1853
Net Cash Flow:
$-10.38M
1W Performance:
-7.78%
1M Performance:
-18.08%
6M Performance:
-86.50%
1Y Performance:
+0.00%
1-Day Range:
$0.194
$0.2141
1-Week Range:
$0.1924
$0.223
52-Week Range:
$0.1924
$33.66
Liminatus Pharma Inc Stock (LIMN) Company Profile
Name
Liminatus Pharma Inc
Sector
Industry
Phone
213-273-5453
Address
6 CENTERPOINTE DR., LA PALMA
Compare LIMN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIMN
Liminatus Pharma Inc
|
0.1957 | 7.70M | 0 | -2.58M | -10.38M | -0.1853 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Liminatus Pharma Inc Stock (LIMN) Latest News
Weekly Earnings: Is Liminatus Pharma Inc Equity Warrant stock undervalued right nowMarket Activity Summary & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Aug Patterns: Can BPMC maintain its current growth rate2026 Fundamental Recap & Accurate Technical Buy Alerts - baoquankhu1.vn
Update Report: What are the future prospects of Liminatus Pharma Inc Equity Warrant2026 Buyback Activity & Real-Time Buy Zone Alerts - baoquankhu1.vn
Liminatus eyes clinic with CD47-blockade antibody IBA-101 - BioWorld MedTech
Liminatus Pharma to initiate Phase 1 clinical trial for IBA101 antibody - TipRanks
Liminatus Pharma’s IBA101 May Represent the CD47 Innovation Addressing Anemia and Thrombocytopenia in Advanced Immuno-Oncology - Bitget
Liminatus Pharma announces planned phase 1 clinical trial of IBA101, a next-generation CD47 blocking antibody - marketscreener.com
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody - The Manila Times
Liminatus Pharma Announces Planned Phase 1 Clinical Trial Of Iba101, A Next-Generation Cd47 Blocking Antibody - TradingView
New 'don't-eat-me' cancer antibody to be tested in Liminatus lung trial - Stock Titan
LIMN Stock Price, Quote & Chart | LIMINATUS PHARMA INC-CL A (NASDAQ:LIMN) - ChartMill
Aug Movers: Is Liminatus Pharma Inc stock a top performer YTD2026 Trends & Smart Money Movement Tracker - baoquankhu1.vn
Reviewing Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN) - Defense World
Insider Trends: Is Liminatus Pharma Inc Equity Warrant subject to activist investor interestWeekly Trade Recap & Reliable Volume Spike Alerts - baoquankhu1.vn
Liminatus Pharma Stock Surges to Record High After Regaining Nasdaq Compliance - MSN
Aug Mood: Is Liminatus Pharma Inc a strong growth stock2026 Breakouts & Fast Moving Stock Trade Plans - baoquankhu1.vn
How Liminatus Pharma Inc. stock responds to policy changesQuarterly Earnings Report & Expert Curated Trade Setup Alerts - Naître et grandir
Winners Losers: Is Liminatus Pharma Inc Equity Warrant subject to activist investor interestJuly 2025 Drop Watch & Weekly Momentum Picks - baoquankhu1.vn
Liminatus Pharma Lowers Quorum Requirement in Bylaw Amendment - TipRanks
Aug Update: Is Liminatus Pharma Inc stock a smart retirement pickJuly 2025 Retail & Reliable Entry Point Trade Alerts - baoquankhu1.vn
LIMN Earnings History & Surprises | EPS & Revenue Results | LIMINATUS PHARMA INC-CL A (NASDAQ:LIMN) - ChartMill
LIMN Should I Buy - Intellectia AI
Basic earnings per share (basic EPS) of Liminatus Pharma, Inc. – NASDAQ:LIMNW - TradingView
Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Up 4,357.6% in February - Defense World
LIMN PE Ratio & Valuation, Is LIMN Overvalued - Intellectia AI
Free float of Liminatus Pharma, Inc. – NASDAQ:LIMNW - TradingView
Critical Analysis: Liminatus Pharma (NASDAQ:LIMN) and Athira Pharma (NASDAQ:LONA) - Defense World
Net income of Liminatus Pharma, Inc. – NASDAQ:LIMNW - TradingView
Liminatus Pharma, Inc. Dividends – NASDAQ:LIMNW - TradingView
Liminatus Pharma, Inc. Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation - The Ames Tribune
Aug EndMonth: What are Liminatus Pharma Incs recent SEC filings showingQuarterly Profit Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Earnings Risk: What are Liminatus Pharma Incs recent SEC filings showing2025 Top Gainers & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Can Liminatus Pharma Inc. Equity Warrant stock deliver strong Q4 earnings2025 Historical Comparison & AI Forecast Swing Trade Picks - mfd.ru
Trend Recap: What is QSIAWs valuation compared to sectorProfit Target & High Conviction Investment Ideas - baoquankhu1.vn
Liminatus Pharma Completes $4 Million Public Equity Offering - The Globe and Mail
Liminatus Pharma Prices $0.29 Equity Offering, Nets $3.46 Million Under Securities Purchase Pact - TradingView
Aug Highlights: Can Liminatus Pharma Inc Equity Warrant be recession proofJuly 2025 Short Interest & Verified Stock Trade Ideas - baoquankhu1.vn
Liminatus Pharma prices $4 million public offering at $0.29 per share - Investing.com India
Liminatus Pharma prices 13.8M shares at 29c in public offering - TipRanks
Gold Down 3%; Medtronic Earnings Top Views - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering - Bitget
BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - The Manila Times
Bond Watch: What dividend growth rate does Sun Communities Inc offerWeekly Market Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
History Review: Is MasterBrand Inc benefiting from interest rate changesPortfolio Growth Summary & Accurate Intraday Trade Tips - baoquankhu1.vn
Is Liminatus Pharma Inc. Equity Warrant subject to activist investor interestTrade Volume Report & Long-Term Investment Growth Plans - mfd.ru
Published on: 2026-02-15 22:28:13 - mfd.ru
Can Liminatus Pharma Inc. Equity Warrant be recession proofTake Profit & Safe Capital Investment Plans - mfd.ru
Why Liminatus Pharma Inc. Equity Warrant stock is recommended by analysts2025 Market Overview & AI Driven Price Predictions - mfd.ru
Bond Watch: Can Xtant Medical Holdings Inc. (XMS) stock withstand sector downturnsJuly 2025 Volume & Long Hold Capital Preservation Tips - mfd.ru
Is WisdomTree Europe Hedged Equity Fund stock among top earnings playsJuly 2025 Price Swings & Comprehensive Market Scan Reports - mfd.ru
Liminatus Pharma Inc Stock (LIMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):